PKI - Earnings call transcript Q3 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen. And thank you for standing by. Welcome to the Third Quarter 2020 PerkinElmer Earnings Conference Call. At this time all participants are in a listen-only mode. After the speaker's presentation there will be a question-and-answer session [Operator Instructions] At this time, I'd like to turn the conference over to Mr. of President Vice Kipp, Investor Relations. Bryan begin. please Sir,

Bryan Kipp

Executive to Thank quarter third the and are and Chief welcome Vice Mock, With you, Good afternoon, call Chief President Singh, operator. Financial the Prahlad and XXXX President on Jamey Senior PerkinElmer me and Officer; earnings Officer. call. conference

and www.perkinelmer.com. a being of from of section the earnings have be Please this release, is press will at call note you live our If November copy you on not webcast Investors XXXX. our received XX, our website may one archived website get until

views should our to rely representing on statements any for significantly of differ outlined today. today's today. which everyone or those of forward-looking made in involve you Before which have the we statements forward-looking necessarily statements comments detail begin, forward-looking change, by results press company's afternoon we date our update and Any need our of our the only today We in actual in after but those are be filings. harbor to our financial or or as so not release disclaim may expectations we certain forward-looking or factors, may remind SEC matters in that our SEC also objectives, include, on statements, intentions. any are a earlier to obligation other represent from Statements not this projections of may the These statements due of and any views any made projected future risks variety company's statements statements this to, limited The estimates suggested earnings call uncertainties. plans, even issued forward-looking safe as other of as outlined in filings.

extent, during measures. in our attachment the is introduce we comparable During and Officer measures of use release. the Executive reconciliation now reconciliations earnings the during call to that the of financial we financial attachment, GAAP this will as that plan am be financial non-GAAP non-GAAP an provide Prahlad call A Prahlad? to will available reconciled directly GAAP Singh. to referring non-GAAP Chief I this To we measures measures to this pleased certain President we to are not use PerkinElmer, to call, most press promptly.

Prahlad Singh

Thank you, And Brian. good afternoon, everyone.

to reinforced employees that further and XX,XXX Our our results continue go year-to-date reality. and above beyond,

rallied As proud and team. improving I our by lives organization's in It humbled everyone I mentioned, previously is of our immensely DNA. is XXXX. what together remain throughout PerkinElmer has how have within impassions

we on customers that of crisis outlined this our keeping the at pandemic stronger expansive employees COVID-XX, with this against principles from guiding period during to excellence serving and company our the fight emerge the difficult in remain a company. utilizing our onset join While and capabilities as the North safe, Star,

We are ago. the environment positioning the The what will post year undoubtedly organization a might also like. future different a we actively imagined for look COVID-XX be from world

could and built agility Over and direction position organization, have the dramatically in challenges of are positioned market and the moving responsiveness our past commercial new enhanced to relationships. adjacencies, I business are to as the organization, into of months, tomorrow. a ahead XX expanded we not our an resiliency, headed confident from as Due lines more we, right strength. tackle that be an we

and delivered contributed third during million high we sales, of XX%, XX% our the the second which organically, results details of our Adjusted strong results. outstripping significant once X,XXX quarter. in a expanded the decline points multi-decade earnings million profitability quarter While, related last financial guidance Jamey achieved will Moreover, again driven portfolio. quarter's surpassed COVID basis nearly financial approximately company $XXX operating of the year-over-year, Results grew our far quarter. communicated $XXX Revenue a third high. during call. watermark non-COVID Overall, margins X% within and for we by share our the

of earnings to and per quarter compared adjusted share Our almost doubled XXXX. flow grew adjusted cash third the free XXX%,

reinforced unique I core as leads is are through have our leading whether throughout with impactful automating PerkinElmer and science, XXXX, development, novel product success. history method with of part it research, publishing at As fundamental a workflows science introductions, our

customers. solutions, in we constantly Our about the is view that months efforts the personally our one world something a limit teams that combat of chasm pandemic. over It are with story. is And FDA the the talked X for COVID Take SARS out insights. test month, We've discovery how number chapter extensively how of tests science experimentation lowest between leading has with the about to to help PerkinElmer's next Last few example. as I'm of our our ranked XX resonates passionate the PerkinElmer Scope in thinking cultural about can terms and past of as ideology real propelled pivotal narrow our reality to it a detection.

recall, assay If we to first market you with PCR not February. a were in

goal in conversation. speed to often COVID quickly test as the as important in launch innovation, testing possible a never While was is our to be

combat to of test aim the the growing was a address develop that high-quality can needs our customers Our help health pandemic. and will and providers

begun clinical shift stood tests out. certainly as occurred, recognize Over are community not the the has COVID this to has that PerkinElmer past And created few equal. months, all has

setting. and XX a scientific pharma of several entirely published studies more life the made almost or the studies Additionally, We tools decade scientific our studies in to research journals. and to internal over are external published effort that primed as over focus team there future. to year, to to that the rare it or in published is we increase PerkinElmer the we It additional company journals. shift members past are accepted A are led the Studies in cutting-edge see had quarter, metric an by reputable beginning the quarter. accepted of for sciences significantly fourth leading track velocity continue was done during frequently, academic have important an were we consciously ago,

year-to-date, However, today well as XX lines increasingly COVID-related a With more new products our during those quarter, than more primed kind experienced non-COVID-related richest and breakthrough a over pipeline commercialization are and products launched than my To products for blurring. is dozen the on. in give fourth I sense career. of new certainly we you are have the innovations just XX of product the focused

Bringing for Severe The of tests our DNA X-linked hands the SCID newborns assay for assay During on workload by multiyear EONIS increasingly to life XLA, quarter, increasing on the a improving a in treatments in of positive point Immunodeficiency, extraction, that was are debilitating atrophy, for and not and around hope assay. recent multiplex genetic allows third this this efficiency being impact gamma complexity. workflow quality by and included multiplexing panels Combined Driven This in daily global with we assay will a IVD combination the spinal three advances these approval. CE screening SMA SCID received patients screening for SMA, process RT-PCR muscular anemia, simultaneously the maximum world. have afflicted mandated X and automation disorders.

clinical COVID-XX Syncytial also partners multi-analyte marking and traction nascent health recently ago, care molecular us is upcoming new making panel were with future. in a the governments the PerkinElmer A academic of was CE diagnostics year well RT-PCR industries season. across laboratories, institutions, the COVID-related a PerkinElmer in pleased product RSV, Virus, to receive of fall the terms B and detection approvals, Respiratory the respiratory systems, other for - influenza flu ahead and PCAM SARS-CoV-X single key of for a direct launches for positions player we industry. influenza test A, Commercially, In

nine past handlers over instruments to throughput our instruments have have our months, the we in nucleic and hundreds of added than tripled asset sizable X,XXX installed liquid installed base over However, to more extraction high well base. worldwide,

unique to taking technology a which are to In up is the give various expanded our external eight matter to COVID-XX a process It XX,XXX fully PerkinElmer signing high outfitted X. a only day that affinity magnetic by support the market, an starting California, perspective, feat as in lab in in in well lab you in up bead collaboration State new RNA running the share and solution locally. employees testing impressive best-in-class possible fully are partnership and week, as samples and has of of samples Lighthouse month Valencia, breaking would by weeks Earlier And extraction normal the accreditation through offerings made Social visited from various RNA To of sample-to-answer as as lab set extraction this our blood Department this we a November as environment, has State Kingdom, and contract, months. one to testing of this We accredited partners. ground made full running for was lab XX per sacrifices and samples. some departments with beat of United the have XX become ready as part the California's a taken process, Care. workflow earlier in first the magnetic saliva Turnkey binding our whole began Health a with I since our typically recognized lab of

it of reinforce in presence unique pre-COVID our intend clinical expertise us to capabilities of expand time our a world, position to While beyond during important we laboratory our proactively I to need. help and a scope is think a post-COVID partners puts that breadth our not in do extreme

help combat and we is this it any can. way believe living to are We times, pandemic exceptional duty that our in we

been is While find top want certainly solution on of ever-changing be fronts, about on year organization the this many world. I of PerkinElmer. am passionate working a in multiple proud helping challenging part to personally at myself has bottom, people. be reflecting our From We it a to to I for us how

around which Last said have live impact and day communities in volunteer day, us for I before, participated where we the is our a we it work. world special on month, personal employees annual in PerkinElmer's all. the As

across remains this classes volunteered in to the difference we the communities the the a for and donating to children ways to virtual trees rural the same, trash Although make pandemic, from and in were blood hosting goal year collecting different planting globe, areas. due

update globally. to Our moment impact was CSR want a to I our felt on efforts. also people take

released latest just data report we we in are While June, next consolidating already CSR past our our update. CSR this for

stakeholders, interests employees, to that ensure all put of the Our stakeholder and and concern. including with serving investors line our suppliers in priorities CSR groups, are in place teams customers, are we currently

partnerships with living for to world new customers I we closing, and And In the address As of make who reiterate what an also new with and challenges our happen. science with increasingly is perspective, and plus and and and the with will awareness of with the will normal the can PerkinElmer millions complex solutions scientific and throughout company because chance our important planet. the and can difference. impactful a and together, learning individual, put we want hope and that right do possibilities future markets seemingly ourselves, around this to will our business for we or geographies from around employees, is ones people PerkinElmer are. while working we we with every Through we both that on ones to to what who the of We cope to the unbelievable generate we stand drive kind lives community through say, and align a is new innovations, continue make global we develop it what partners filled for, challenges the day. employees we collaborations, most impact of community expand partners customers is means own stand people's the first indirectly the we

we the We much have XXXX is there we to and into pandemic, to over of humbled beyond. the already move the glimpses final the can quarter turn Jamey. more inspired, up continue I'll as ready we making this occasion for all and the that to the gearing impact an during quarters already as of but follow. seen in do year I'm now rose and call

Jamey Mock

evening, Thanks, that into of team beyond. well PerkinElmer everyone. I and confident our start, positioned I be not Prahlad, is and To more could XXXX prouder and good echo Prahlad.

of equity our relationships in dozens with won and organization Over build not our products, year, partners, down. expanded the past is slowing customer have markets, and foster new significant new we our multiple presence

sciences December of front To are excited in host dive virtual the the about life to point, deep plan a and on we future. community investment We all for the truly laser-focused X. on opportunities that us

and up We for we walk discovery, this through enterprise where informatics session, topics have exciting teed will businesses. our

Additional in information specifics coming event will the the weeks. on be communicated

information. section people the Before under I Investors our presentation results, I discussing of quarter to posted on begin earnings third financial has want been that website remind our financial call our

will pleased our I and financial my level, organization with end At to end prepared markets I'll results. third well. will always, provide and extremely quarter metrics, third are fourth remarks guidance. our begin additional served with the on quarter, As I and continues then some high The by color we year-to-date a execute quarter highlighting

As engagement quarter. business second versus the customer sequentially expected, and activity improved

third to quarter, is compared tailwinds. we year, exchange than the million the revenue which communicated. X% During to third better net and included foreign acquisition increased XX%, what last X% revenue and grew quarter XX% $XXX had previously X% Organic

representing since onset mid milestone serve As certainly Prahlad by contributed and a our continue markets. customers reproductive business million businesses excess business headed China Asia strong applied DAS organically, applied each geographic strength X,XXX single are On COVID-related total the extraction helped ongoing quarter. quarter led per of total products earlier, the of. productivity adversely birth Europe the earnings leverage, operating more food all the We as was over their originally solutions, and diagnostics, by and in by during see Pacific in the both to Solutions, Adjusted in in in mix RNA basis, $X.XX third expanded offset in and Operationally, XX% be $XXX XX% all of digits. Analytical this impacted in share than performing our sciences our By more pressures in In versus and Adjusted territory with volume increased the grew the place safety measures to and total, XXXX. with immunodiagnostics and quarter, third better genomics Discovery modest quarter. XX.X%, trends life sales, mentioned to fight pandemic. by our offset diagnostic COVID-XX pandemic, grew X,XXX declined to as negative contributing representing pleased non-COVID than primarily X% PCR quarter. fight end third health of digits, performance XX% margins we Strength in pleased remained franchise. and are overall tests of basis were increased million have a in propelled Americas of we approximately quarter extremely we programs. our sales, business against of $XXX double markets rates proud XX% declines into than organically. anticipated points the

our our into with Looking drivers segments, the start key further within let's Diagnostics business.

Europe earlier remarks, XX% quarter the third As organic as the robust the momentum, mentioned revenue than and regions in in Americas year. with basis drove my of compared increased an growth more organic both to last doubling on

world. molecular product business Our on business across all quarter handling with Nucleic momentum liquid and over liquid Both Applied broader Genomics respectively, testing acid position handling our and third broad-based XX into XXXX. share extraction the strong testing in portfolio gained with extraction lower and sequentially have assays digits nucleic automated grew while growing times, XX%, times declined our of immunodiagnostics declined health globe, and RT-PCR Pacific mid-single as demand digits. across post-COVID growth Pacific. Europe serology Asia a expected. organically, Reproductive by in while EUROIMMUN mid-single was digits. and single Demand high Americas Meanwhile, newborn Europe particularly driven double increased declined for Asia Applied versus strength and six Genomics geographies our the to of expand well way, in posting lines. over digits, and acid led XXX% growth the increased pre-neonatal

Early double year down Europe, safety America that year-to-date digits and indications single to to impacted rates birth related rate to birth rebounded rates Newborn and North are utilization COVID-XX by high prior low be worldwide. declines are rates China levels continued while Western in measures.

XX% versus and sciences. digits, biotech improved is organic XXX% XX% by digits, declined informatics and and far single-digit estimate quarter. delays increased the market, not is biotech academic reagent XX%, and experienced third Pharma year. government driven in a was and in normal, single sequential quarter researchers. end demand. Applied Organic Turning Solutions. to we growth XX% declined activity up last in declines revenue approximately to approximately XX%. & Food same revenue period By in mid declined strength organic We mid-single benchtop X% to Discovery the improvement in enterprise Analytical high continued life back impact funding services, discovery double-digit to growth, the that at to with positive activity pharma for to as over Europe to academic experienced Americas markets behind government pointing XX% approximately declined reopening utilization

double sequentially do upgrading enhance However, and improved declined by exiting material food Europe processing quarter Trends food more the XX% items. the to Meanwhile, third tax the digits budget X%, declined led down by were contributor by and our improving the companies below not in productivity and other as from excluding was to solutions. Asia was fourth a and environmental while digits. million, XX%. interest safety the single second any high Net quarter, sequentially in other for expense declined All industrial $XX and cannabis, third the Pacific, the high Perkin year, rate consistent during than made line quarter. was midstream Shifting X%, investments Americas quarter. currently which grew digits. approximately strong we single the expense flush line last adjusted for in anticipate quarter regions

million the the $X.X to finished XX%. free an flow adjusted with achieved of We and billion the flow Free We quarter. million balance in Turning cash of cash quarter of $XXX was approximately sheet. conversion cash. debt $XXX

last over the flow adjusted year. adjusted turn beginning compared monthly of the down of nine ratio was quarters XX% DSO to months flow free linearity, Closing up has The we earnings a from extremely of adjusted we been are performance, function first year. XX%, XX% last period from of the XX% share books Year-to-date, year. of improved growth, three the per debt-to-adjusted conversion including our comparable cash on cash approximately reduction fold and all and related progress COVID-related growth free the milestone payments. with demand. organic XXXX, flow XXX% with free our over growth, and XX%, Overall, pleased quarter the conversion COVID-XX first the cash improvements EBITDA California X.X Finally, net excluding process since least at of we encouraged are times, exited year-to-date a XXXX anticipate by adjusted X potential

to Turning fourth guidance. the quarter

including $X.XX foreign COVID-related revenue organic to is from of We million $XXX a growth revenue, revenue billion to X% from XX% guidance benefit Embedded billion, million to representing of reported forecasting approximately growth, X% an in of to X% to are product this representing XX% line. $XXX $X.XX organic and XX% exchange. demand non-COVID decline our XX%

quarter, terms the forecasting adjusted of of earnings per guidance range a to $X. for we In share are $X.XX

are rate to the jurisdictions, profits page this in We higher earnings of of is last tax detailed third increased in presentation. to due assuming all a second XX% tax rate our quarter

exchange foreign the For adjusted million progress full to share now expenses, the has to negligible closing, better In XX% and anticipate a the rate for tax million. over we year approximately $XX future. PerkinElmer other organization made headwind $XXX count position year, of past in a our significant interest average and the

and We our are customers. is ahead for better excited we will what serve how

even this doubt of and operating like time, would are for all to open have questions. We to at will years be strong from I that more a coming Operator, call the stakeholders. our we foundation, fruitful no

Operator

Kumar of comes or from the comment Vijay line ISI. first Instructions] [Operator question Our Evercore from

open. is line Your

Vijay Kumar

the And Hey, on a had guidance. taking my one one I guys. Thanks a for follow-up picture quick question. on big Maybe question.

at Because, to you guide declines, on perhaps base positive QX, peers why in? the your parser? guess does one, base the contracts business. California $XXX of business, assuming flattish any is some the to I million, are seeing to the million have baked look And Turning maybe when mid-single Jamey, $XXX

Jamey Mock

Vijay, doing Thanks, and well. Yeah. hope you're

non-COVID versus we're the which I'd trends. third with looked we the versus I'll the speaking, comfortable backlog, a when as and third feel entered generally COVID. We've break our our guide, So similar it taking quarter, fourth entering approach kind when at down did we quarter, say has order very quarter. we and we at looked grown of entered We've

exit So of non-COVID, as accelerated fast the market are the they second quite not the rates seeing are improve, quarter. we end as the at but

noting, continue, continue lines they'll substantial think fourth And year. in high growth However, they last product us. we if material if also be end. substantial if for quarter of fourth of the the they be revenue in happens, was or end. as quarter. XXXX, quarter don't in worth the It's assuming We're at the Vijay, fourth that no very was two low we'll Cannabis as well quite the had XXXX, something fourth in cannabis at quarter we the informatics

we So if you probably be by we'd think points. exclude those three two, better

to X%, So probably instead X%. be down of we'd X% down X% to

quarter. So comps. DAS same vicinity in X% in It to be third minus the came probably those in will due the

exclude in you it an if comps, few start However, Diagnostics down ex-COVID fourth then And months. DAS And or would revenue was seen XX%. quarter. the uptick those last positive XX% be the we've over

And so be single down high will that, assuming we digits. are that

and the $XXX UK we the to kind low $XXX is is way standpoint, to of $XXX which million California. $XX $XXX digits, was call specifically million range, that assuming and extra - derived question We're third is the to $XXX on at we asked business we're business million. million those the quarter. that the the COVID labs, million you million million then $XX $XX million From the to comps. $XXX you Yes, to base mostly about single to have gets explains base So million, of million. number The it overall California but low $XX non-COVID. to in It it adding in labs a the for closer an in $XXX the each is two minus million

noting how general, our revenue. block COVID this are And upside of on guidance. this thought assumes kind of we significant any are the revenue positivity about of in any we our none this to in down, material and that's downside they happen, think now, across to guidance, But the right lockdowns Should planning significant of rates COVID Vijay. not obviously, I non-COVID up any world. is have it material that all worth could going

Vijay Kumar

And extremely helpful, for one Jamey. big Prahlad. That's one then

some to think towards some at making, astronomical. earnings. I look these you giving of guys right, the forward Prahlad, guess, I story. here because credit, well. I'm ago. of sustainability, point, your Perkins sustainability. in were looking some you're hasn't the headwinds through next base some in XXX% revenues here like COVID to going isn't mean, Are numbers, market chapter curious, numbers about the as XX you I'm the one But The way the molecular deployment? And growth I question it these be right? And of is for is biggest next these stock Thank And comments acted the right from flows you not the right, that's think you. year? to a when Maybe diagnostic the the player perspective. Perkin company, cash for about these, a incremental talk come think space? COVID your does What strengthen in was in capital position about months the

Prahlad Singh

the very way would a been it. at mean question, of to giving we lot it, good It's look think a thought Vijay. I have I I obviously,

looking upon I'm areas extremely on across NPI from personally NPIs that be we it, we team well, we principles on. on cadence and innovation tell to strength focus to be guiding that right? where months, and primary have the thinking will opportunities Number that some I is focused most things a regular innovation. are the what to focused no has can three very are And looking and talked light positioning that the my few organization, mean, past me and now the have dives next will on building of the that attention Over now, of the at that I we exciting we areas, the company sort - are markets. disruptive efforts at three years? strong. acceleration, muscle lots future. focusing through three deep allows over for where but into X of how the will it sort that both And in is having As maybe what confidently into I one this non-COVID, that exercised different driving we fundamentally you have focus X on throw of doubt ideas. the been I And right? of it COVID COVID, about, adjacent on There quality of and and my key way the new expand I'm are very reviews, need we

The second one capital are deployment, We great position. around right? a in

We have in you past diagnostics. gained molecular over we our expanded firepower as And have year, the mentioned, markets, now. share around new presence and

both this So current diagnostic actively and to deploy on can to layer life that capital we enhances looking market. additional franchises, are the so positions the further bolster we side the on sciences that in capabilities our

capability would in go vivo Cell me leading a Let content hand-in-hand look and cells to the researchers have, have level. right? versus a imagers. an we and have position you selection with which allow with and high subcellular changed give example, that that we As imaging tools screeners at in a separation would - from disease population target the detection we investigate characterization,

or these a is for tools adjacency manipulation So us. cell separation detection, around natural additional

year, bolster around an And the So deep that we efforts the last one continue teams is R&D. I've last diverse recall, DX, commercial example bench that's the if on to our Over United and talent the building would been deployment. that from our we people stream. capital an you has DAS combined focused organization front. and on

that under take focus that future. And my feel alliances How umbrella. putting and bring attention these commercials confident three the that within So I we we and do we those the Now COVID? do that we on. am how have across focus partnerships our focus of because why globe opportunities areas the - on personally we are the one that's is have about built

Vijay Kumar

guys. helpful, That's

a think cell of separation cap. and of billion the Thanks, that's worth you probably adding perhaps detection, I was lot ahead single a up market $X thing guys. missed only maybe another to

Operator

Thank you.

the question comment from comes line of next Dan Stifel. Our Arias from

open. is line Your

Dan Arias

were you I of thank wanted sort Good about of that sustainability. some on ideas point of talking hit afternoon, Prahlad, Vijay's on follow-on you. to and kind on those

on starting maybe the top diagnostics. with line, Just

being brings, couple think could that you you they're segment You there? post just a birth that expected growth? initiatives good on What's of you accelerating COVID? you some reproductive on back immuno that how aside of of highlighted thoughts how the of you shape Can again, outside about to you leaving rates the that non-COVID And growth in might and double-digit in once early what where your And is a normalized and in and think side, health look segment DX, of do feel expectation these being in talk organic the move some have portions drive guess, I world. you diagnostics in times, get period, periods? COVID XXXX pass confidence about into the your on ultimately, to COVID on how we a when recovery the growing a have of

Prahlad Singh

said, great the Yeah. of don't let's And magnitude foreseeable the birth right? we Dan. this No, headwind start reproductive expect future. for a with be you question, As pressures health, to current the rate

remarks, that the uses that of product is it for EONIS portfolio will COVID, point arena segment can I prepared right. this same the expect diagnostics that, like just workflow currently a where We we normalize. outside example moderate is of used that because being as into some conditions at molecular that But during particular gave the my you bring

DMD, panel all new reproductive thought disorders are expansion are Dan, menu you liquid based. already to example, And as around components use from they the off extraction health, place either of that all in at being the use looked forward look the base. you that You these we the as SMA, are now the same use same the or installed and handling, molecular RUS at most PCR, same an

or the So which in-house other we side, diagnostics, away on molecular the is opportunities. looking the the moving immunoassay of we look again, together technology as well new that assays to several have immunodiagnostic on inorganic the are with we from expanded immune working methodology immunoassay or and also sort new either base globe. are side, Similarly, across matches installed at there that put

we And I I EUROIMMUN that important should to factor portfolio out Adding the bringing and be where said, have of a started Excentis in be already slowing new to see that that have that's from of autoimmune some recovery pressure comes continue are to wearing will platform it. growth. probably portfolio and right. - sometime allergies. around to the [ph] we've we've Now the for add think an the of year. on we next seeing in China. down, that very productive, and moving on expand detection even just we'll that's as rate that we in portfolio, that short-term to signs named portfolio see of because - in And one a side not going is is allergy place autoimmune that is diseases being And pressure The continuing Autoimmunity, our that people masks, the the by

So base that sort built of Dan. there are installed extraction with the we've we at ways are around already our looking that various expanding portfolio portfolio, today our

Dan Arias

that with that's it share honestly, choice in see with signs the once time and areas to. business going sticking of come going on of creating they some Maybe you'll for sounds term you elevate explanation one selling there. buying the happen, and you're seeing when of that are that things Okay. or what because down mind but the stickiness like be partnership options, of Are to go kind they strategic areas are multiple now helpful you a you're longer That's it, that can the just think opportunities deals idea. make is mean, labs, hopes sample during there quite get a you'll like that, creating term. to I in you and prep sort longer is the awareness similar have that Genomics the a bit

Prahlad Singh

Yeah. units mean have put we X,XXX more have than that I been installed.

Now these are put labs this they're while have infrastructure - we place. in also COVID, focused look, aware on that

to Now we've put to this installed set in competency leverage have and be to base plans beyond we COVID. able that got place up

around are a again, that have - we partnerships, we be this put customers And have solely partnership, what around that that Those already and team that this what to discussing focused efforts hey, can will taking function we Jamey's alliances workflow. these So announced. through this gone several put in we in fact, and now forward. can else of an not us, are else this with extent absolutely, those the we through announced has establishing

Dan Arias

it. a Thanks lot. Appreciate Okay.

Operator

you. Thank

Our Derik America. Bank next comes the Bruin from question of line of De comment from

open. is line Your

Derik De Bruin

But rebound Hi, And [ph] good business I thinking rebound think one? afternoon. core next you there. that thinking of you're to how the for I what think on of bit think of modeling parts. how about think the about in side care for mean DAS sides I should Can sort for trying of we took about I sort know we of the we for talk sense a the a about just talk we of just back potential DAS business get is the lot is little What a particularly about diagnostics Can year? 'XX? and sort pent-up in thinking and just - it's early do mean bounce I'm demand? on we're side, can much about a a there's you Dan moving core

Prahlad Singh

Sure. doing are Derik, you hope Yes. well. Hey,

in I comps reasonable mean, off to I coming think start we're, year fairly So general, with. this

I positive, heading mentioned we I OneSource. Informatics, business XXXX, moving think remarks that grower year. I is is here. my the will that into forward and throughout a sciences, prepared Discovery life think continued think, now strong still see uptick continue the seen we've we to in a

relatively and DAS of and easy spending business, starting we XX% comps; probably see to have XX% the should we're So you the A, that's to the sciences is expect, B, business. life

year-over-year. feel about cannabis we So good not that. Food, the have issue will

you - next $XX was in XXXX, or XXXX, And you million. if I cannabis this remember remember, to year, guess, it's if nothing. So

comp a issue. that election do and restaurants on little DAS, and in is starts nicely, And shutdown. have through to particularly to and upon But be And we don't environmental have understand A, start I'd a of funding lived already to that So NPI. life happen and an I industrial bit, processors not with and open are, it's uptick in Food growing will and got But where the been probably might comp it as but think comp. whatnot. will Informatics. significant has easy it it's to food amount we fact, life think if anticipate a what And where whatnot, depending hard levels snapback the addition, we relatively environmental have kind goes easy have will well. at I should least sciences, fair of you've big will rebound stable and steady. up in anymore then an I difficult be sciences and not industrial start The or should comp should thing say has; and general, a only again.

our So Prahlad been mentioned weekly of all earlier, holding segment reviews with it he's leaders.

our up fourth We the XX% uptick to R&D. We the in ticking are further in quarter. plan up It's third quarter.

of there improved that for out So well should coming is and a in NPIs beyond business. cadence DAS the XXXX bode

Jamey Mock

will the immune And so the life that, side. seeing looking just sciences I started we've life also well Sciences around think Life to path increased Derik, add that also and business on to investments on Research, at and governments research responses, the side, CDCs some from viral sciences for bode

Derik De Bruin

interesting automated of that was extraction the comment. benefiting free in people Got extraction And for how going an maintain on mean, - sample fact more them. market? of - a was from - And of that RNA also, thinking headwind extraction and with of competitors it's certainly one like you're going about I that heat, just seems sample one. Can like sort It the you're thinking the sort it. it RNA space preps it. your lay about is the to bile, the evolution you talk there's dynamics of about

asking sort and like about do about. that question RNA to that think you extraction once the of and sustainability how your going, So shifts of goes market - How share it business do things you again, Vijay nature? was

Prahlad Singh

I months cows that And like installed And confidence stickiness COVID, home, the or or becomes beyond whether COVID and might and look where the what need diseases to installed you around The is be But three low But that be going definitely quarters, think that's continued do in is I this having able is we will stay. I the is surveillance the surveillance easy our at extraction here cost. our the the want move want. customers want, that of for at proved away it, base the our base. to I is they the our cost is use what a at can debate higher - at just us are come it I that parameters with months our gives the three stickiness the mean, is months. would is think customers' over that's of right right what look of that important. the more base installed more importantly, relevant has there - as all portfolio past Derik, future. And why what relevant from goes stickiness base. And if workflow is extraction there COVID to an into to that workflow that we they till nine of important. three you've six are the that they very COVID yield, that got the we infectious look go way a provide a numbers product for. think Getting

Derik De Bruin

Great. Thank turn I'll you. the in back queue.

Operator

you. Thank

Our of next question or from comment Peterson line Tycho JPMorgan. comes from the

is open. line Your

Tycho Peterson

how Hey, I start California to And you remind thanks. read go the I the us I'm about I'm that do could side to ask start take of the up the then when bit where into up to trying separately two think I some volume going tailwinds. PCR those just and on panel, then actually much know forward versus you capacity again? other test? XXXX. think, XXX,XXX the Can just of U.K. a starts little and you And - serology could tests. get respiratory stand-alone COVID from to on goes XX,XXX also analyte the labs, think you the California standpoint? samples a to to take multi pick California. And with respiratory talked in maybe do

Prahlad Singh

Yes.

to will in we XXX. I could ready capability be think that would in up around start-up next a where Tycho, the lab to go right, XX, to building California of And up we be capacity fact, you're a XXX,XXX. to So of up the week,

Jamey Mock

XX,XXX.

might at like point the then quarter, the ready some in XXX,XXX be end the By I XX,XXX. first something at think the for it quarter, working state during with we're quarter. them. first And of the be

Prahlad Singh

flu asked, around mark. gotten Tycho, And CE as we've you pack,

We school that the but labs large set go populations a might are on pack, under awaiting FDA school RT-PCR the extent healthcare thought There might yet under or RT-PCR. I not into others go workflow that the populations the of that, that two which can flu depends And the have have test. approval. think go ones whereas, tests, on we flu how and yet up think the is or to capability different a be which pure decides, I might the up within And kids deviate we that for be segments the go proportion has determined. been it once to we through, around state what and have pack

Tycho Peterson

there? on outlook up Or Okay. when that what's mid-next And again? do then serology, to you think your year? pick that Is starts

Prahlad Singh

as quarter, in first effect. quarter vaccines first I - taking start the probably the I is sometime think it mean,

that's along with the vaccine start trend the up will serology Tycho. picking think efforts, I

Tycho Peterson

think rates in China. shifting from negative for can just you there. Can still then company on and And talk other so I think But - gears, - and the you your when to Okay. return you? levered you're that's only birth you obviously we've factors China just heard far may growth

Prahlad Singh

mean, we we have a think that, But our and been two flow impact. I as autoimmune as if seen through us, now it respiratory, to DAS. have seeing have from One, started the ones you in those have while weightage And we diagnostics that China mentioned, there I pressured in are been than of, Yes. for a China right? has even at - stronger DX, things now, think I look distributors. in China again,

sell-through look So as distributors - our we continued the as flow-through or increase. we our forward, to distributor from has

to would we improve. quarter, that quarter this next to and continue improve I into and will as continues So look that it say

Jamey Mock

already mid been seen sciences the Yes, mean, Food I And has I agree. Applied down on then life and we've single. low turn kind of DAS to would Tycho, single side, China. in positive

anticipate quarter that year year first an less steadily uptick, environmental, the and and positive seen grown that uptick. will throughout particularly that turned Diagnostics we with in has DAS have the would next I easier think in be So comps it I - and continued the industrial And of obviously by about, we mask, in matter. we'll everybody long little influenced EUROIMMUN. allergy by a and the a things see. rates uptake there's a if that birth bigger turn talked Diagnostics, share would wearing but is Allergy Prahlad there. for is But China term... But positive And DAS

Tycho Peterson

on just And one then and - the then operating last DAS last margins.

You business investments. margins to Was you analysis be of and DAS areas earlier. other guess should the those you A, you're particular for out? continue incremental investing that cellular called forward flagged call pulling main investment? can think some area some that of as we kind about to the under I pressure

Jamey Mock

the DAS, That's to you're though, speaking a on specifically question great Tycho? -

Tycho Peterson

Correct. Correct.

Jamey Mock

are XXX Yes. decisions. One them is, for points like see Yes, both in has that And quarter, been or under of probably half DAS the reasons. two that. conscious is basis we're down of you'll about pressure something

life our analytical our our OpEx ready about increased want the it's half portfolio, that, and we've side, mentioned we On to sciences get portfolio, portfolio. We've of for that R&D. our earlier food

increase to continue we So R&D.

to mentioned that and the in particularly channels, work on on people do work that had and general. past in to continue marketing We our sales food. there, some we I've

our other as is part principles the the this conscious layoffs keep we're we've probably of at OpEx which soon no we X safe, now. making the line, plants that we've the Similarly, margin made any And that be had half earlier, and half, upticks, should okay. the as decision volume on Prahlad should a is of decision, to was gross outlined that be our globe. fine, about of employees a on investment and which So across

whatnot to laid we've as off. haven't variances due the overhead and the has anybody had even unfavorable factory So volume declined,

be back, and bit as of the unfavorable ready, And think the a will we little short-term so workforce volume comes seeing that variances. therefore, we're just

Tycho Peterson

Thank Okay. you.

Operator

comes the from [Operator from next and Instructions] Beuchaw comment Steve of Wolfe Research. question Our line

open. is Your line

Steve Beuchaw

here. Hi, time thanks for the

to I things okay. ground maybe the angle, but back a do covered, with I has different come if want bit of that's think couple and most a little of of been a

haven't of here, see the the that that of talk which logic clarity of in XXXX. on First, disclosure all here, it's getting I'm sort more more wonder, surprised on a I if popping congratulations that the done. obvious. that the contract. mean really up headlines frankly, extent initiative and pretty happening. I initiative could I But and to you thing though, of I little California seen that appreciate you about

necessarily to that So speak could just U.S., not you you but the in globally. what on see front,

screening, if competitors wonder a talk you of within a of your mentioned, comments as Derik bit context I overall could about, lot of is, Second one today. little the made

One they one market was think have wonder follow-up. if of the that it that to the could speak they between next splits you and And kind made year, comments half testing, to as I I of relates dynamic. and half PCR then antigen.

Prahlad Singh

Okay.

our some it's because first other the there globe, one, request. good partnerships which some of discussions we announced there the publicly going partner's I that across other Steve, on, On then are think we a haven't are right? have But question,

what said I and my remarks, should our think California, months. XX focus like these longer right, on alliances governments how get and I action that and take in have is do term partnerships. prepared done we as weeks, we've taken crisis And eight of But mean what I really are sort within do I So alliances these, larger importance such during as think pandemics when these, a times of states into gear. forge

build that is not on not the really that. our is strategy. lab, we So part really, beyond become But is and what flawlessly focus how a are these to that reference we of strategic is something our execute it intent not do - on

We with building are got California, decade-old three on lab this labs. that we've and around the of and is doing this. state a Because relationship partnership

that's your think antigen the I at So way around look To R-TPCR. the question it. I and between would second split

and from especially when kit our you you you gold increase false detection with negative standard. beyond increase a level pooling. of belief Our XX-fold the moving level it's on of of expected of lowest singular test test, at the a could that diagnostic of to to think - it level detection of the research in and that - of is a shows look detection, get, XX% RT-PCR XX%. And limit a that The there's the rate perspective by COVID is

data to pandemic especially And out so for by highly have be an are a going it's those role. I negative, an flow there continue accurate, is Did test impact the and in infectious to early XXs having the the missed So play think have impact. you does loads XXs, there another by of contagious, diseases that Having even is viral for or that important, test, antigen sensitive is if assays. high an may false which question?

Steve Beuchaw

it's if think is, follow-up giving some know you relates the made uptake multi-pronged serology. amount I past contemplating fair. in are of some But to serology. approach do then on clinical it comments update goes - multi-layered wonder you've the the then Thanks. don't could looking context But residual is within that possibility know a might on two-parter. us a And talked around actually serology about where trials. Very any think you a I thinking And but my that? the that term, That's right of if One the be? fair give there's of uptake you've comments of to from a you're serology, a beyond number timing ways. I what you I the could know at your that? of immunities of different scale around around you lot it clarity

Prahlad Singh

the cellular I cell in idea going really that a we'll vaccine I second guess COVID-related as immunity, example. the testing both be And question be so or saying vaccination is are is - next as talk being insight, it's products impact reason about a and your right? really think And And have the I think think important. But over To at few how that think serology? Yes. quantitative I'm assay and talked how at will immune good based important See, looking on - about on crystal I earlier that, around T yours. is can months. because vaccine what partner a I've we that pipeline and of we would it that ball an on is and the to investigating antibody what it's the that my be. more the the think hopefully, for looking we the honestly the impact as of big for neutralization responses couple

as we where will today I have for serology and move think relevance importance then it So biggest epidemiological will we are from beyond where I impact. to think gain vaccines and the more testing. that That's

Steve Beuchaw

am than is much sure help. much, Thank sophisticated ball the all But I mine. your crystal I you. more appreciate

Operator

Thank you.

Our the Doug of line Schenkel from or question from next comment comes Cowen.

open. is line Your

Doug Schenkel

guys. Hey

a as versus we the more hope quantitative can offset COVID-XX proves lot detail durable on you And qualitative. XXXX $X that you about XX% hoping a generate I'm term. base, to be Thank we it of say, any a how XX% revenue If lot you would you for in the have that. not going - for all So long to earnings. that if pandemic? ways assume provided EPS on CAGR, get a has annual XXXX to use to you grow at, to in been been if that was track

by go initiatives as occurring were all away questions. result are you that and year, revenue simple COVID-XX of point next so the to end two a One, So for of you XXXX? think XXXX, if some the relationships abates pandemic share in at in a related in than growing actually such the pandemic do secondly, scenario, lot earnings XXXX? a you a put in path in per $X And in there would to better a position XXXX is do

Jamey Mock

will benefit we to put installed the place. we base from your that, answer definitely is yes, question have the So in that

XXXX, on asking give that. If not to I'm our to I know... you what us going EPS Doug, going be is an to you don't are in estimate give

Doug Schenkel

I'm of not… course, Yes,

Jamey Mock

Yes, for a couple reasons. of

that the markets the But Prahlad's customer we're lot install capital to a playing a deployment. free flow base on of base, we have. our are generated in, spending additional cash back For of lot it we innovation, points, earlier we've that also, on

the I the So of flexibility it company. think increases

- to not least I trajectory, answer but already for that, So that were this that, to think boost directly, further question think sure. our if ability on should your we meet I at beat

Doug Schenkel

better of in much, And a for what at than much cash then growth, question second free Okay's. while. that you've quarter. least is, on about conversion, how flow know talked in terms XX% seen we've the I

great. said, that's All operating that line. seeing would it the would higher, been intuitively, So I lot have we're at thought a given have what

generating You're ton of a of ton spend. without revenue a operating accompanying

this Did actually hear were back year? that I next trend I down And does could actually expecting wrong, year. heard if it I might that number that, maybe why in that. prepared from just number you to sorry the go I And So right, I disconnect? you right? a be I higher? your next remarks, conversion And that up, through If about heard making isn't Jamey walk this standpoint heard it thought down why

Prahlad Singh

flow anything said going free cash down. I think don't I about Yeah.

like $XXX every of non-COVID So net inventory, a our side the conscious to made which on we've put Dough, exactly XX% million XX% we much do of is inventory, to perspective, but income. into year built decision, build we

absent see think it's informatics do COVID of we have will we non-COVID thing And flow inventory think cash products that uptick backlog, And as the the was and - quarter. of would look to related, year-to-date. next be to side well probably COVID XXX% available. we a So into substantial build which to we've right outside two-thirds and got the the at that walking is cannabis. free And we that at because an backlog the

year-to-date, free to that. in just actually, further related it will the one conversion we're So shape. thing, is a the more COVID we mean be I a future, in wonderful think put actually cash point And while flow drag. on

So and the days if a to dollars that there's on you I We inventory. of million XX think assume hundred couple in million built about $X.X payment of million volume, of $XX balance of of terms couple hundred receivables. terms, there's billion of sheet probably a still XX

the the the that sheet much California working capital. balance we that to cash will basically million believe of excess net collect income But the be and of prove we funded includes quarter. lab we on and that So the outfit this to eroded future fourth $XXX in none we will

Doug Schenkel

QX Which beyond. you, and should all benefit to

Prahlad Singh

right. That's

Doug Schenkel

Thanks All guys. Okay. right.

Prahlad Singh

you. Thank

Operator

concludes I our would Ladies closing remarks. session. you. to gentlemen, over and Thank turn for the this that question-and-answer Mr. At Singh to time, like conference any back over

Prahlad Singh

Thank you, operator. your you Again, questions. for thank

organization with said stronger as our earnings you updates is We we providing supporting the everyone PerkinElmer, proud gratified even forward beginning, an I call. Thank really confident quarterly to and I that doubt the on look have clearly I'm of I'm As together. fourth that how we emerged crisis and leading has very are further no valued science, and that feel at this from for company. I resonating. and

Operator

Ladies and program. for you gentlemen, the participating in thank This conference. today's concludes

You wonderful may disconnect. have Everyone, now a day.

Revvity (RVTY) 28 Oct 202020 Q3 Earnings call transcript